METHODS: IRB approved, retrospective review was performed on 383 consecutive non-metastatic patients who underwent definitive RC at a single National Cancer Institute (NCI) designated comprehensive care center between 2001-2014. Zip code derived proxies of socioeconomic status were collected in reference to patient primary residence using US Census data, in addition to characteristics of referring facilities including size, teaching status, and cancer center designation. Travel distance was estimated via straight line distance calculated from latitude and longitude. Multivariable logistic regression analysis was performed to identify factors associated with delay to cystectomy, defined as > 12 weeks from diagnosis of muscle invasive disease to RC. Patients residing outside the US were excluded from analysis.
METHODS: IRB approved, retrospective review was performed on 383 consecutive non-metastatic patients who underwent definitive RC at a single National Cancer Institute (NCI) designated comprehensive care center between 2001-2014. Zip code derived proxies of socioeconomic status were collected in reference to patient primary residence using US Census data, in addition to characteristics of referring facilities including size, teaching status, and cancer center designation. Travel distance was estimated via straight line distance calculated from latitude and longitude. Multivariable logistic regression analysis was performed to identify factors associated with delay to cystectomy, defined as > 12 weeks from diagnosis of muscle invasive disease to RC. Patients residing outside the US were excluded from analysis. CONCLUSIONS: In an urban environment, distance to treatment facility was not associated with delay to RC. Delay was associated with characteristics referring institutions, including cancer center designation. Further investigation is warranted to determine if consolidation of care to designated centers for complex disease processes such as bladder cancer may improve patient outcomes.
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MP96-17 LOWER SERUM ALBUMIN LEVELS ARE ASSOCIATED WITH LONGER LENGTHS OF STAY (LOS) FOLLOWING CYSTECTOMY: THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM
Rohan Bhalla*, Li Wang, Sam Chang, Mark Tyson, Nashville, TN INTRODUCTION AND OBJECTIVES: Serum albumin levels have been reported to be a valid measure of nutritional status for epidemiologic studies. However, contemporary population-based epidemiologic data evaluating the effect of preoperative albumin levels on LOS after cystectomy and urinary diversion is limited. In this study, we measure the relationship between preoperative serum albumin level and hospital LOS and hypothesized that decreasing preoperative albumin levels would be associated with increasing LOS. Such an association would strengthen the importance of preoperative nutritional optimization prior to cystectomy.
METHODS: Data was acquired from the 2014-2015 National Surgical Quality Improvement Program database. We identified 2,469 adult patients who underwent a cystectomy between January 1st 2014 and December 31st 2015. The primary outcome was hospital LOS and the primary exposure was preoperative albumin. We fit proportional odds logistic model with patient-level variables that were either known to be associated with increased LOS or that we had hypothesized would be prior to model fitting. We allowed all continuous variables to have a nonlinear relationship with the primary outcome using restricted cubic spline with 5 knots.
RESULTS: Multivariable proportional odds logistic regression determined that preoperative serum albumin was independently associated with LOS (OR: 0.81; 95% CI: 0.64-1.02; p<0.001). Figure 1 demonstrates that LOS increases significantly for patients with a serum albumin level of less than 4 g/dl. Other significant predictors include older age (OR 1.56; 95% CI 1.21-2.01; p<0.001), elevated BMI (OR 1.48; 95% CI 1.17-1.86; p<0.001), and non-Caucasian patients (OR 1.7; 95% CI 1.34-2.18; p<0.001).
CONCLUSIONS: This study provides evidence that lower preoperative serum albumin levels are associated with increasing LOS. Efforts to optimize a patient's nutritional status prior to cystectomy undoubtedly have many benefits, including a shorter LOS.
Source of Funding: The project described was supported by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
MP96-18
IMPACT OF PROSTATE CANCER THERAPY ON URINARY INCONTINENCE AND QUALITY OF LIFE
Andrew Wang, Paul McClain*, Robert Given, Norfolk, VA INTRODUCTION AND OBJECTIVES: Prostate cancer therapy is known to affect urinary symptoms in men, and its effect on quality of life can depend upon which type of treatment is received. This study is a retrospective review of a large database of men who underwent surgical prostate cancer treatment to assess the impact of therapy on quality of life in prostate cancer patients.
METHODS: A total of 501 patients who underwent treatment for prostate cancer at a single institution from 2004-2014 were reviewed. The patients in this database were stratified into three groups with respect to the type of therapy received-robot-assisted laparoscopic radical prostatectomy (RLP), brachytherapy, and cryotherapy. Urinary incontinence related quality of life (HRQoL) was assessed at baseline and again at 1-60 months after therapy using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. Preoperative and postoperative urinary incontinence scores were compared using a Student's t-test.
RESULTS: Baseline patient characteristics were similar between each treatment group. Diabetes was the only comorbidity correlated with urinary symptoms. Baseline urinary incontinence scores were 93.3, 94.5, and 88.2 in the RLP, brachytherapy, and cryotherapy groups, respectively with a significant difference between the RLP and cryotherapy groups (p ¼ 0.046). Urinary incontinence worsened in all three groups at the first follow-up (2.2 months) after treatment (p < 0.0001). The corresponding scores at long term follow-up were 72.0 (p < 0.0001), 78.1 (p < 0.0001), and 83.1 (p ¼ 0.165). The RLP group Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1301
